<?xml version="1.0" encoding="UTF-8"?>
<p id="p0055">
 <bold>For lopinavir-ritonavir</bold>: A randomized, controlled, open-label trial
 <xref rid="bib14" ref-type="bibr">
  <sup>14</sup>
 </xref> suggested, for patients with severe COVID-19, lopinavir-ritonavir treatment beyond standard care did not significantly accelerate clinical improvement or reduce mortality (
 <italic>P</italic> &gt; 0.05). For patients with different clinical classifications, a retrospective study
 <xref rid="bib15" ref-type="bibr">
  <sup>15</sup>
 </xref> found that lopinavir-ritonavir combined with other antiviral drugs can shorten the time of viral nucleic acid turning negative and improve the results of lung CT imaging (
 <italic>P</italic> &lt; 0.05), but the effect on clinical improvement was not significant (
 <italic>P</italic> &gt; 0.05).
</p>
